A Randomised, Placebo-controlled, Double-blind, Single Dose, Cross-over Study to Evaluate the Efficacy and Safety of Orally Inhaled Tiotropium + Olodaterol as Both a Fixed Dose Combination and a Free Combination (Both Delivered by the Respimat Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Randomised, Placebo-controlled, Double-blind, Single Dose, Cross-over Study to Evaluate the Efficacy and Safety of Orally Inhaled Tiotropium + Olodaterol as Both a Fixed Dose Combination and a Free Combination (Both Delivered by the Respimat Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2014

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Olodaterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 11 Jun 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 16 Apr 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
    • 16 Apr 2014 Planned End Date changed from 1 Jul 2014 to 1 Jun 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top